Alcan to Sell Its Share in Dutch Smelter to Klesch

Alcan announced today that it has reached an agreement in principle with UK-based Klesch & Company Limited (Klesch) regarding the sale of its Vlissingen smelter in the Netherlands. Alcan owns 85% of the smelter and Hunter Douglas, which holds the remaining 15% interest, has confirmed its intention to sell its interest to Klesch. Terms of the agreement were not disclosed.

"Since October 2006 we have been studying all alternatives for our site in Vlissingen. Klesch is in a good position to offer new and sustainable solutions, and I am glad that we have found a path forward to ensure a future for the plant," said Michel Jacques, President and CEO, Alcan Primary Metal Group. "This transaction clearly demonstrates Alcan's ongoing commitment to value-based portfolio optimization and is aligned with our business strategy and target of improving Alcan's competitive position on the cost curve," he added.

The final agreement is expected to be completed following the conclusion of the consultation process with employee representatives in the Netherlands and France. The transaction is anticipated to close in the summer of 2007. The intended sale would include a commercial agreement that would ensure ongoing billet and sheet ingot supply to Alcan's engineered product plants and to Hunter Douglas as well as to third party customers.

Klesch & Company Limited is a private equity firm that owns a variety of businesses. In recent years, Klesch has completed several significant transactions; namely, Transamerica Maritime Containers (known as TAL International Group) from Aegon N.V. group purchased for US$1.2 billion, as well as eKabel Hessen from Deutsche Telekom for (euro)1.2 billion. The Vlissingen aluminum plant employs approximately 700 people and has a smelting production capacity of 200,000 tonnes, with a turnover of approximately US$ 600 million in 2006. The site primarily manufactures aluminum billet for the European engineered products market.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.